ExpreS2ion Announces Formation of Oncology Scientific Advisory Board
Hørsholm, Denmark, November 3, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces the establishment of an Oncology Scientific Advisory Board (OSAB). The six initial members of the ExpreS2ion OSAB bring a depth of knowledge in oncology, breast cancer, clinical trials and therapeutic HER2 vaccines, and will contribute to the development of ExpreS2ion’s proprietary HER2-cVLP breast cancer vaccine, ES2B-C001. The OSAB will serve as advisors, potential contributors to the planned clinical studies and participants in Key Opinion Leader events for the scientific community and investors.
Chief Executive Officer Bent Frandsen comments:
“It is with considerable pride that we announce the establishment of our Oncology Scientific Advisory Board, comprised of six renowned scientists whom I am confident will facilitate the development of ES2B-C001 in a manner that optimizes its potential. As ES2B-C001 gains momentum on its progress towards clinical development, ExpreS2ion is at a critical juncture in which the OSAB will augment the Company’s already deep R&D competencies. On behalf of ExpreS2ion, I welcome our new OSAB members to the ExpreS2ion story and look forward to developing a therapy that will potentially benefit women suffering from HER2-expressing breast cancer worldwide.”
Chief Medical Officer Mattis Flyvholm Ranthe comments:
“This team of experts brings unique and best-in-class specialists together, providing critical input to ExpreS2ion’s clinical development program of our therapeutic HER2 directed vaccine, allowing it to meet the needs of patients and physicians alike. In a dynamic treatment landscape, input from Key Opinion Leaders is crucial in maximizing the likelihood of success in our efforts to develop a safe and efficacious product. Our pre-clinical data gives us sound reason-to-believe regarding anticancer effects, but equally important is aiming for the right patient populations from the start, and here our experienced Key Opinion Leaders provide expert input. These are world-class leaders in the field of HER2 expressing cancers, and will be able to provide critical input into overall development, trial designs, and patient populations. This is a huge step for ExpreS2ion, bringing us close to the critical milestone of getting our vaccine into clinical development, and eventually to the right patients.”
The inaugural members of the ExpreS2ion’s OSAB
Dr. Giuseppe Curigliano, MD, PhD
Dr. Curigliano is an Associate Professor of Medical Oncology at the University of Milano and the Head of the Division of Early Drug Development at the European Institute of Oncology, Italy (IRCCS). He is a clinician and researcher specialising in early drug development for patients with solid tumours with a special commitment to breast cancer. Dr. Curigliano is recognized among the leading experts in the world within the field of HER2 expressing breast cancer. He serves the European Society for Medical Oncology (ESMO) as the Chair of the Guidelines Committee and is a Council Member. He was awarded the first European School of Oncology (ESO) Umberto Veronesi Award in Vienna in 2017, and the Fellowship of the European Academy of Cancer Sciences in Paris in 2017. Dr. Curigliano serves as editor on several scientific journals and has authored or co-authored more than 650 peer-reviewed scientific papers and several chapters in oncology textbooks.
Dr. Javier Cortes, MD, PhD
Dr. Cortes is a Doctor in Medical Oncology, and Head of the International Breast Cancer Centre (IBCC) in Barcelona. Since 2006, he has held leading positions within breast cancer research with leading institutions and universities. He is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO), and is a member of expert panels that develop the treatment guidelines for metastatic breast cancer. He is the author of more than 380 publications, primarily focused on breast tumours and new drugs, and more than 800 communications at different conferences. He actively participates in the development of numerous international clinical trials.
Dr. Ulrik Lassen, MD, PhD
Dr. Lassen is a Professor at University of Copenhagen, Department of Clinical Medicine. In 2017, he was appointed Head of the Department of Oncology at Copenhagen University Hospital, Rigshospitalet, Denmark. As a Clinical Oncologist he has been working with Phase 1 Oncology trials since 2005 and is ESMO board certified in Medical Oncology. As Professor in Clinical Oncology he has a special focus on personalized medicine. Established the Phase 1 Unit at Rigshospitalet in 2005, and established Copenhagen Prospective Personalized Oncology program (CoPPO) in 2013. Dr. Lassen is member of, and has held leading positions in Danish Association of Cancer Research and Danish Society of Clinical Oncology. Dr. Lassen has (co-)authored 297 peer reviewed publications.
Dr. Michael Andersson, MD, DMSci
Dr. Andersson is a Clinical Oncologist working as consultant at the Breast Oncology Unit in the Copenhagen University Hospital, Rigshospitalet, Denmark since 1998. He has special interest in HER2-positive breast cancer and has published on and been Principal Investigator in several national and international studies of HER2-positive early and metastatic breast cancer. Dr. Andersson has authored or co-authored 143 peer reviewed publications.
Dr. Rupert Bartsch, MD
Dr. Bartsch is an Associate Professor of medicine at the Medical University of Vienna in Austria and serves as the director of the Breast Cancer Programme at the Department of Oncology. Prior to joining the Medical University of Vienna, he was Head of the Breast Centre at the Elisabethinen Hospital in Linz, Austria, and was temporarily based at the German Breast Group in Neu Isenburg, Germany. Dr. Bartsch has a longstanding clinical and scientific focus on breast cancer and brain metastases. Together with his colleagues, he has published over 150 articles in peer-reviewed journals, among them Nature Medicine, Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology and Clinical Cancer Research.
Dr. Daniel Lenihan, MD, FACC, FESC, FIC-OS
Dr. Lenihan has been active in cardio-oncology, for over 25 years. He has previously held positions at MD Anderson Cancer Center in Houston, Texas, Vanderbilt University in Nashville, Tennessee, and Washington University in St Louis, Missouri. Dr. Lenihan is the Founder and Immediate Past President of the International Cardio-Oncology Society (IC-OS), a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. Dr. Lenihan serves as editor on several scientific journals and has authored or co-authored 216 peer-reviewed scientific papers and authored several books and book chapters on cardio-oncology.
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.
Tags:
